F. Erdkamp

516 total citations
14 papers, 185 citations indexed

About

F. Erdkamp is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, F. Erdkamp has authored 14 papers receiving a total of 185 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in F. Erdkamp's work include Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Nanoparticle-Based Drug Delivery (2 papers). F. Erdkamp is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Nanoparticle-Based Drug Delivery (2 papers). F. Erdkamp collaborates with scholars based in Netherlands. F. Erdkamp's co-authors include C. J. Rodenburg, Ninja Antonini, J. Tol, A. Cats, Linda Mol, C.J.A. Punt, Allert H. Vos, Jolanda Schrama, Manon J. Pepels and A. G. M. Hoofwijk and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Journal of Cancer.

In The Last Decade

F. Erdkamp

14 papers receiving 176 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. Erdkamp Netherlands 5 145 82 37 32 29 14 185
Sreelakshmi Mallappa United Kingdom 6 146 1.0× 32 0.4× 26 0.7× 50 1.6× 69 2.4× 14 219
Marla Lipsyc United States 3 107 0.7× 25 0.3× 36 1.0× 46 1.4× 30 1.0× 6 141
Keitaro Shimozaki Japan 10 191 1.3× 115 1.4× 39 1.1× 31 1.0× 56 1.9× 33 257
K. P. Theall United States 4 95 0.7× 27 0.3× 17 0.5× 70 2.2× 23 0.8× 9 140
Jean‐François Tamby United States 4 63 0.4× 29 0.4× 31 0.8× 10 0.3× 40 1.4× 9 170
László Landherr Hungary 8 122 0.8× 62 0.8× 23 0.6× 61 1.9× 11 0.4× 20 191
Caterina Accettura Italy 7 104 0.7× 40 0.5× 27 0.7× 55 1.7× 35 1.2× 14 170
Jo Dent United Kingdom 5 149 1.0× 76 0.9× 20 0.5× 15 0.5× 49 1.7× 9 177
Alec S. Koo United States 7 112 0.8× 97 1.2× 22 0.6× 23 0.7× 30 1.0× 10 222
Els Monsaert Belgium 6 174 1.2× 61 0.7× 24 0.6× 87 2.7× 60 2.1× 17 228

Countries citing papers authored by F. Erdkamp

Since Specialization
Citations

This map shows the geographic impact of F. Erdkamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Erdkamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Erdkamp more than expected).

Fields of papers citing papers by F. Erdkamp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Erdkamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Erdkamp. The network helps show where F. Erdkamp may publish in the future.

Co-authorship network of co-authors of F. Erdkamp

This figure shows the co-authorship network connecting the top 25 collaborators of F. Erdkamp. A scholar is included among the top collaborators of F. Erdkamp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Erdkamp. F. Erdkamp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Erdkamp, F., et al.. (2011). Toxic dermatitis in patients treated with Taxotere® (docetaxel): three case reports. International Journal of Clinical Pharmacology and Therapeutics. 49(1). 46–48. 2 indexed citations
3.
Reyners, Anna K.L., Willem M. Smit, Michael Schaapveld, et al.. (2009). Adding the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin in first line for stage IC-IV epithelial ovarian cancer: A randomized phase II study. Journal of Clinical Oncology. 27(15_suppl). 5545–5545. 1 indexed citations
4.
5.
Punt, C.J.A., J. Tol, C. J. Rodenburg, et al.. (2008). Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). Journal of Clinical Oncology. 26(15_suppl). LBA4011–LBA4011. 104 indexed citations
6.
Punt, Cornelis J.A., Miriam Koopman, J. Douma, et al.. (2007). Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group (DCCG) phase III study. Journal of Clinical Oncology. 25(18_suppl). 4012–4012. 7 indexed citations
7.
8.
Pepels, Manon J., et al.. (2006). Sclerosing peritonitis: an unusual cause of ascites in a patient with systemic lupus erythematosus.. PubMed. 64(9). 346–9. 21 indexed citations
9.
Erdkamp, F., et al.. (2003). 168 A phase II study of docetaxel, epirubicin, and cispiatin with G-CSF (ienograstim) support in patients with advanced ovarian cancer. European Journal of Cancer Supplements. 1(5). S54–S54. 1 indexed citations
10.
11.
Chan, Stephen L., N. Davidson, Elona Juozaitytė, et al.. (1999). Phase III study of liposome-encapsulated doxorubicin (TLC D-99) and cyclophosphamide (CPA) vs. epirubicin (EPI) and CPA in first-line treatment of metastatic breast cancer (MBC). European Journal of Cancer. 35. S315–S315. 3 indexed citations
12.
Peters, Femke P., et al.. (1996). Abscess of the spleen. The Netherlands Journal of Medicine. 48(1). 11–14. 1 indexed citations
13.
Wils, J., et al.. (1996). PP-7-6 Dose dense epirubicin (E) and paclitaxel (P) with G-CSF in metastatic breast cancer (MBC). European Journal of Cancer. 32. 46–46. 1 indexed citations
14.
Bos, L.P., et al.. (1995). An uncommon cause of anaemia in ulcerative colitis. The Netherlands Journal of Medicine. 47(1). 18–20. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sreelakshmi Mallappa Breakdown of academic impact, for papers by Marla Lipsyc Breakdown of academic impact, for papers by Keitaro Shimozaki Breakdown of academic impact, for papers by K. P. Theall Breakdown of academic impact, for papers by Jean‐François Tamby Breakdown of academic impact, for papers by László Landherr Breakdown of academic impact, for papers by Caterina Accettura Breakdown of academic impact, for papers by Jo Dent Breakdown of academic impact, for papers by Alec S. Koo Breakdown of academic impact, for papers by Els Monsaert
Rankless by CCL
2026